Description

Danirixin (GSK1325756) is an orally active, selective CXC chemokine receptor 2 (CXCR2) antagonist with 78-fold lower affinity toward CXCR1 (CXCR2/CXCR1 IC50 = 12.5/977 nM by competitive binding against 0.225 nM [125I] CXCL8). Danirixin blocks agonist-induced neutrophil CD11b expression in vitro (IC50 = 420/890 nM against induction by 10 nM human CXCL1/rat CXCL2 using rat/human whole blood) and prevents lung neutrophils influx in rats in vivo following aerosol lipopolysaccharide or ozone challenge (ED50 = 1.4 and 16 mg/kg, respectively).

For research use only. We do not sell to patients.

Specification

Formula	C₁₉H₂₁ClFN₃O₄S
CAS Number	954126-98-8
Molecular Weight	441.90
Purity	≥98%
form	powder
color	white to beige
solubility	DMSO: 2 mg/mL, clear (Warmed)
storage temp.	-10 to -25°C
SMILES string	O=C(NC1=CC=C(C(S([C@H]2CCCNC2)(=O)=O)=C1O)Cl)NC3=C(C(F)=CC=C3)C